Results 171 to 180 of about 3,917,698 (342)

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami   +6 more
wiley   +1 more source

paclitaxel-induced fixed drug eruption: a rare adverse drug reaction case report [PDF]

open access: hybrid
Rithunandana Sreeja   +3 more
openalex   +1 more source

Fixed drug eruption due to foscarnet. [PDF]

open access: bronze, 1990
G M Connolly, Brian Gazzard, D A Hawkins
openalex   +1 more source

Dermatology 2.0: Precision medicine for inflammatory skin diseases

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Digital immune mapping of transcriptomics profiles from inflammatory skin disease biopsies enables precise molecular diagnosis, quantification of immune modules and personalized therapy selection by matching dominant immune signatures to targeted treatments.
Jeremy Di Domizio   +4 more
wiley   +1 more source

Cell Therapy for Periodontal, Soft‐Tissue, and Craniofacial Regeneration

open access: yesJournal of Periodontal Research, EarlyView.
The clinical translation of mesenchymal stem/stromal cells (MSCs) represents a major advancement in dentistry, especially for periodontal, soft‐tissue, and craniofacial regeneration. However, several challenges remain to be addressed, including the absence of standardised protocols, limited scalability, regulatory hurdles, a lack of well‐controlled ...
Kamal Mustafa   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy